



**Business Update & Full Year 2023 Earnings Call
April 10, 2024**

Speakers on Today's Call



- **Thomas Meyer, Ph.D.**
 - Founder, CEO & Chairman



- **Covadonga Pañeda, Ph.D.**
 - Chief Operating Officer

Forward-Looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the success of strategic transactions, including licensing or partnering, with respect to Altamira Therapeutics' legacy assets, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2023, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.



Corporate & Strategy Update

Highlights

Transitioning to Become a Focused RNA Delivery Company


- **Progressing in RNA delivery business**
 - Entered into second collaboration (mRNA vaccines)
 - Potential new applications identified
- **Partnering of legacy assets initiated**
 - Partial spin-off Bentrío business (OTC allergy nasal spray)
 - To partner AM-125 in 2024 (vertigo nasal spray + multiple other opportunities in CNS)
 - Unlocking intrinsic value
- **Improved financial strength**
 - Substantially reduced operating expenses / cash burn
 - No more financial debt, rebuilt shareholders' equity



RNA Delivery Business

Growing Potential for OligoPhore™ / SemaPhore™

Addressing Major Challenges in RNA Delivery



- IV administration, reaching extrahepatic targets
- Strong endosomal release (>> lipid nanoparticles)

Extensive proof of concept

- Successfully tested in vivo with siRNA and mRNA in 15 different disease models, 30+ papers published

Body of evidence keeps growing


- Oncology (ZBTB46 mRNA): immunostimulatory tumor microenvironment, restricted tumor growth; potentiated with PD1 immune checkpoint inhibitor
- Osteoarthritis (DNMT3B mRNA): reduced bone sclerosis, cartilage degeneration, synovitis and pain sensitivity

Novel applications

- Insertion of peptide into adeno-associated virus (AAV) vectors significantly enhances cell transduction

Leveraging the Platforms

'Picks and Shovels' Business Model



Objective: license technology to biotech & pharma partners for use in their own RNA drug product development programs




- Evaluate OligoPhore™ + certain non-coding RNAs in the regeneration of damaged heart tissue following myocardial infarction



- Evaluate SemaPhore™ + mRNA vaccine(s)
- Lower mRNA loss during cell entrance may allow for using lower doses and thus result in potentially more effective and efficient vaccines


AM-401 & AM-411 Flagship Programs

Demonstrating How OligoPhore™ Works – Up to IND or Phase 1



AM-401 for KRAS driven cancers

- Mutated KRAS found in 1/5 of all human cancers
- Altamira's *polyKRAS^{mut}* siRNA targets G12C, G12V, G12D, G12R, G12A, and A146T, covering 90.9% of KRAS mutations in pancreatic, 65.3% in colorectal, 80.0% in non-small cell lung cancer
- Significant reduction in tumor volume growth *in vivo*
- Patent filed; IND targeted for 2025



AM-411 for rheumatoid arthritis (RA)

- Knock down NF-κB (p65), a key checkpoint in RA inflammation, with siRNA
- Nanoparticles take siRNA to inflamed tissues to act locally
- Significant reduction in inflammation, bone erosion, ankle swelling, and arthritis score *in vivo*
- IND targeted for 2025



Legacy Programs

Partial Bentrio® Spin-Off

First Step in Process of Strategic Repositioning



- Sale of 51% of Altamira Medica AG
 - Cash consideration about \$2.3 million
 - Buyer is Swiss private equity investor
 - CYTO retaining 49% of capital
- CYTO also entitled to 25% of
 - future license income
 - Medica's value appreciation in case of a sale
- Financial gain: CHF 5.2 million (IFRS)
- Going forward: reduction in Bentrio related expenditures

Significant Upside Potential in Allergy

Strong Efficacy Clinically Demonstrated



- Unique positioning
 - alternative to medicated nasal sprays, or
 - combination with oral treatments such as antihistamines
- Significant growth expected from 2024 onwards
- Collaboration with Nuance Pharma for key CN market
 - aiming for market approval in 2024
 - milestone payments, revenues, royalties (post transfer)
- Pharma Nordic: launch in Norway Q1 2024
- Advanced partnering discussions on North America, Europe and other key markets

Working Towards Partnering AM-125


Next Step in Our Strategic Repositioning



- AM-125 has been developed for treating vertigo
 - Reformulation of betahistine in nasal spray
 - Significantly higher bioavailability
 - Proof of concept in Phase 2 trial
- Partnering discussions ongoing
 - Strong potential especially in U.S.
 - Aiming for transaction(s) in 2024
- \$18 million invested to date
 - Nothing on our balance sheet
 - Any partnering proceeds will go straight to bottom line

Potential Other Indications for AM-125

Betahistine is a Histamine Analog with Potentially Many Uses...



- Histamine plays important role in many behavioral and physiological functions:
 - Appetite, drinking, sleep, wakefulness, learning, attention and memory
- Clinical utility of betahistine shown, among others, in:
 - ADHD, cognitive function in dementia, memory loss, antipsychotic-induced weight gain
- Histamine as target, e.g.:
 - Narcolepsy
 - Tourette syndrome
 - Prader-Willi syndrome



Full Year 2023 Financial Results and Outlook

Significant Reduction in Operating Expenses

<i>Swiss Francs (CHF)</i>	2023	2022 ¹⁾
Other operating income	255,589	9,327
Research and development	(3,035,413)	(14,621,570)
General and administrative	(3,136,275)	(3,401,676)
Operating loss	(5,916,099)	(18,013,919)
Finance income	354,093	565,399
Finance expense	(1,668,475)	(1,211,042)
Share of loss of an associate	(39,557)	-
Loss before tax	(7,270,038)	(18,659,562)
Income tax gain/(loss)	-	7,919
Net loss from continuing operations	(7,270,038)	(18,651,643)
Discontinued operations:		
Profit/(loss) after tax from discontinued operations	3,400,865	(7,876,768)
Net loss attributable to owners of the Company	(3,869,173)	(26,528,411)
Other comprehensive income/(loss):		
Items that will never be reclassified to profit or loss		
Remeasurements of defined benefit liability, net of taxes of CHF 0	31,163	441,277
Items that are or may be reclassified to profit or loss		
Foreign currency translation differences, net of taxes of CHF 0	208,848	61,046
Share of other comprehensive income of an associate	6,869	-
Other comprehensive income/(loss), net of taxes of CHF 0	246,880	502,323
Total comprehensive loss attributable to owners of the Company	(3,622,293)	(26,026,088)

1) Revised for the reclassification of the Bentrico business as discontinued operations in 2022.

Significant Strengthening of Balance Sheet

<i>Swiss Francs (CHF)</i>	December 31, 2023	December 31, 2022	<i>Swiss Francs (CHF)</i>	December 31, 2023	December 31, 2022
ASSETS			EQUITY AND LIABILITIES		
Non-current assets			Equity		
Property and equipment	1	1	Share capital	2,646	236,011
Right-of-use assets	80,110	445,827	Share premium	20,102,873	192,622,406
Intangible assets	3,893,681	3,893,681	Foreign currency translation reserve	4,399,200	258,044
Other non-current financial assets	80,001	194,263	Accumulated deficit	(18,046,002)	(201,431,272)
Investment in an associate	2,417,312	-	Total shareholders' (deficit)/equity attributable to owners of the Company	6,458,717	(8,314,811)
Total non-current assets	6,471,105	4,533,772			
Current assets			Non-current liabilities		
Inventories	-	11,644	Non-current lease liabilities	-	343,629
Trade receivables	-	6,525	Employee benefit liability	346,628	336,206
Other receivables	74,823	755,987	Deferred income	-	932,200
Prepayments	283,832	709,266	Deferred tax liabilities	-	125,870
Derivative financial instruments	247,090	270,176	Total non-current liabilities	346,628	1,737,905
Cash and cash equivalents	617,409	15,395			
Total current assets	1,223,154	1,768,993	Current liabilities		
Total assets	7,694,259	6,302,765	Loan	-	5,869,797
			Current lease liabilities	99,659	117,856
			Trade and other payables	440,414	4,914,404
			Accrued expenses	348,841	1,977,614
			Total current liabilities	888,914	12,879,671
			Total liabilities	1,235,542	14,617,576
			Total equity and liabilities	7,694,259	6,302,765

Cash Flow Statement

<i>Swiss Francs (CHF)</i>	2023	2022
Net cash used in operating activities	(11,511,064)	(8,683,231)
Net cash from / (used) in investing activities	1,444,869	(2,141,837)
Net cash from financing activities	10,621,615	9,831,995
Net increase / (decrease) in cash and cash equivalents	555,420	(993,073)
Net effect of currency translation on cash	46,594	24,277
Cash and cash equivalents at the beginning of the period	15,395	984,191
Cash and cash equivalents at the end of the period	617,409	15,395

2024 Financial Outlook

- Regular total funding requirements for operations and financial obligations between CHF 6.5 to 7.5 million
 - (i.e. without any potential proceeds from partnering)
- Raised \$2.0 million in Q1 2024 from share issuances under “ATM” program with H.C. Wainwright and equity line with Lincoln Capital Partners
- Remaining funding needs to be covered through
 - partnering of legacy assets and / or
 - sale of equity or convertible debt securities

